Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stake Boosted by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 36.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,010 shares of the biopharmaceutical company’s stock after purchasing an additional 3,200 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Intra-Cellular Therapies were worth $1,003,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Norges Bank acquired a new stake in Intra-Cellular Therapies in the fourth quarter worth $268,347,000. Raymond James Financial Inc. bought a new position in shares of Intra-Cellular Therapies during the fourth quarter worth about $76,451,000. Adage Capital Partners GP L.L.C. grew its position in shares of Intra-Cellular Therapies by 266.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 678,000 shares of the biopharmaceutical company’s stock worth $56,627,000 after acquiring an additional 493,000 shares during the last quarter. TimesSquare Capital Management LLC increased its holdings in shares of Intra-Cellular Therapies by 91.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock worth $70,179,000 after acquiring an additional 402,186 shares during the period. Finally, Deep Track Capital LP lifted its position in Intra-Cellular Therapies by 24.9% in the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $167,040,000 after purchasing an additional 399,307 shares during the last quarter. Institutional investors own 92.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Wall Street Zen started coverage on shares of Intra-Cellular Therapies in a research report on Thursday, May 15th. They issued a “hold” rating for the company. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their target price for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $109.70.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $131.87 on Monday. The firm’s 50 day moving average is $131.87 and its 200-day moving average is $118.89. Intra-Cellular Therapies, Inc. has a 12-month low of $66.26 and a 12-month high of $131.98. The stock has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.